Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Low
UBS

David Low

UBS
Wall Street Analyst
★★★★☆
#683
on 13Foresight · ranked by our own returns
65%
Success Rate
+2.4%
Average Return
33 of 51 calls profitable · +23.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 65% of David Low's ratings turned a profit when each position was held for 1 year — averaging +2.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

26 Buy 28 Hold 0 Sell
David's Stock Coverage 17 ratings · 2026-11-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AU:CSL
CSL
 Oct 29, 2026 BUY Strong Buy
+12.2% avg upside
16 analysts
$225.00
12.18% Upside
 +0.7% ·
AU:RHC
Ramsay Health Care
 Oct 29, 2026 HOLD Hold
-14.1% avg upside
14 analysts
$55.60
0.02% Downside
 +0.3% ·
AU:SHL
Sonic Healthcare Limited
 Oct 29, 2026 HOLD Hold
+23.5% avg upside
12 analysts
$21.20
8.41% Upside
 +2.5% ·
AU:TLX
Telix Pharmaceuticals
 Oct 22, 2026 BUY Strong Buy
+103.0% avg upside
14 analysts
$26.00
97.95% Upside
 +3.6% ·
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
 Oct 20, 2026 BUY Strong Buy
+15.6% avg upside
11 analysts
 — -0.4% ·
AU:COH
Cochlear
Oct 19, 2026 HOLD Hold
+30.8% avg upside
15 analysts
$135.00
5.99% Downside
 +11.5% ·
AU:ANN
Ansell
 Oct 04, 2026 HOLD Hold
-22.5% avg upside
9 analysts
$38.70
14.75% Downside
 +1.5% ·
AU:REG
Regis Healthcare Ltd.
 Sep 02, 2026 HOLD Buy
-0.8% avg upside
6 analysts
$5.95
23.92% Upside
 +5.6% ·
AU:IDX
Integral Diagnostics Ltd.
 Aug 27, 2025 BUY Strong Buy
+63.0% avg upside
12 analysts
$3.40
92.64% Upside
 -19.3% ·
AU:PNV
Polynovo
Aug 27, 2025 HOLD Buy
+79.2% avg upside
5 analysts
$1.30
43.66% Upside
 -23.2% ·
AU:NAN
Nanosonics Limited
 Aug 27, 2025 SELL Hold
+56.7% avg upside
7 analysts
$3.90
28.71% Upside
 +39.5% ·
AU:HLS
Healius Limited
 Aug 25, 2025 SELL Sell
+74.4% avg upside
10 analysts
$0.62
25.27% Upside
 +54.5% ·
AU:PME
Pro Medicus Limited
 Aug 14, 2025 HOLD Buy
+30.0% avg upside
9 analysts
$300.00
52.85% Upside
 -42.7% ·
RMD
Resmed
 Aug 01, 2025 BUY Buy
+4.6% avg upside
27 analysts
$310.00
34.80% Upside
 -23.7% ·
AU:M7T
Mach7 Technologies
 Mar 02, 2025 BUY Strong Buy
+319.7% avg upside
5 analysts
$0.78
199.98% Upside
 -27.0% ·
SKHHY
Sonic Healthcare
 Aug 23, 2021 HOLD Hold
5 analysts
 — -21.3% ·
CSLLY
CSL
 Dec 04, 2019 HOLD Buy
+568.3% avg upside
3 analysts
 — +17.2% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Low — Frequently Asked Questions
How accurate are David Low's stock ratings?
Based on the calls 13Foresight could measure, about 65% of David's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, or -1.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Low is currently ranked #683 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on AU:CSL, AU:RHC, AU:SHL, AU:TLX, AU:RMD, AU:COH, AU:ANN, AU:REG, AU:IDX, AU:PNV, AU:NAN, AU:HLS and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.